#### SULFAMYLON - mafenide acetate cream Rising Pharma Holdings, Inc.


-----

#### DESCRIPTION

SULFAMYLON Cream is a soft, white, nonstaining, water-miscible, anti-infective cream for topical administration to burn wounds.

SULFAMYLON Cream spreads easily, and can be washed off readily with water. It has a slight acetic odor. Each gram of SULFAMYLON Cream contains mafenide acetate equivalent to 85 mg of the base. The cream vehicle consists of cetyl alcohol, steryl alcohol, cetyl esters wax, polyoxyl 40 stearate, polyoxyl 8 stearate, glycerin, and water, with methylparaben, propylparaben, sodium metabisulfite, and edetate disodium as preservatives.

Chemically, material acetate is  $\alpha$ -Amino-p-toluenesulfonamide monoacetate and has the following structural formula:



# **CLINICAL PHARMACOLOGY**

SULFAMYLON Cream, applied topically produces a marked reduction in the bacterial population present in the avascular tissues of second- and third-degree burns. Reduction in bacterial growth after application of SULFAMYLON Cream has also been reported to permit spontaneous healing of deep partial-thickness burns, and thus prevent conversion of burn wounds from partial-thickness to full-thickness. It should be noted, however, that delayed eschar separation has occurred in some cases.

### Absorption and Metabolism

Applied topically, SULFAMYLON Cream diffuses through devascularized areas, is absorbed, and rapidly converted to a metabolite (ρ-carboxybenzenesulfonamide) which is cleared through the kidneys. SULFAMYLON is active in the presence of pus and serum, and its activity is not altered by changes in the acidity of the environment.

### Antibacterial Activity

SULFAMYLON exerts bacteriostatic action against many gram-negative and grampositive organisms, including *Pseudomonas aeruginosa* and certain strains of anaerobes.

#### INDICATIONS AND USAGE

SULFAMYLON Cream is a topical agent indicated for adjunctive therapy of patients with second- and third-degree burns.

## CONTRAINDICATIONS

SULFAMYLON is contraindicated in patients who are hypersensitive to it. It is not known whether there is cross sensitivity to other sulfonamides.

## WARNINGS

Fatal hemolytic anemia with disseminated intravascular coagulation, presumably related to a glucose-6-phosphate dehydrogenase deficiency, has been reported following therapy with SULFAMYLON Cream.

Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

## PRECAUTIONS

SULFAMYLON and its metabolite,  $\rho$ -carboxybenzenesulfonamide, inhibit carbonic anhydrase, which may result in metabolic acidosis, usually compensated by hyperventilation. In the presence of impaired renal function, high blood levels of SULFAMYLON and its metabolite may exaggerate the carbonic anhydrase inhibition. Therefore, close monitoring of acid-base balance is necessary, particularly in patients with extensive second-degree or partial-thickness burns and in those with pulmonary or renal dysfunction. Some burn patients treated with SULFAMYLON Cream have also been reported to manifest an unexplained syndrome of marked hyperventilation with resulting respiratory alkalosis (slightly alkaline blood pH, low arterial pCO<sub>2</sub>, and decreased total CO<sub>2</sub>); change in arterial pO<sub>2</sub> is variable. The etiology and significance of these findings are unknown.

Mafenide acetate cream should be used with caution in burn patients with acute renal failure.

SULFAMYLON Cream should be administered with caution to patients with history of hypersensitivity to mafenide. It is not known whether there is cross sensitivity to other sulfonamides.

Fungal colonization in and below eschar may occur concomitantly with reduction of bacterial growth in the burn wound. However, fungal dissemination through the infected burn wound is rare.

### Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term animal studies have been performed to evaluate the drug's potential in

these areas.

#### **Pregnancy**

Animal reproduction studies have not been conducted with SULFAMYLON. It is also not known whether SULFAMYLON can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Therefore, the preparation is not recommended for the treatment of a women of childbearing potential, unless the burned area covers more than 20% of the total body surface, or the need for the therapeutic benefit of SULFAMYLON Cream is, in the physician's judgment, greater than the possible risk to the fetus.

### <u>Nursing Mothers</u>

It is not known whether mafenide acetate is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reaction in nursing infants from SULFAMYLON, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

### <u>Pediatric Use</u>

Same as for adults. (See DOSAGE AND ADMINISTRATION.)

# **ADVERSE REACTIONS**

It is frequently difficult to distinguish between an adverse reaction to SULFAMYLON Cream and the effect of a severe burn. A single case of bone marrow depression and a single case of acute attack of porphyria have been reported following therapy with SULFAMYLON Cream. Fatal hemolytic anemia with disseminated intravascular coagulation, presumably related to a glucose-6-phosphate dehydrogenase deficiency, has been reported following therapy with SULFAMYLON Cream.

*Dermatologic:* The most frequently reported reaction was pain on application or a burning sensation. Rare occurrences are excoriation of new skin and bleeding of skin.

Allergic: Rash itching, facial edema, swelling, hive, blisters, erythema, and eosinophilia.

*Respiratory:* Tachypnea or hyperventilation, decrease in arterial pCO<sub>2</sub>.

*Metabolic:* Acidosis, increase in serum chloride.

Accidental ingestion of SULFAMYLON Cream has been reported to cause diarrhea.

#### To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

# DOSAGE AND ADMINISTRATION

Prompt institution of appropriate measures for controlling shock and pain is of prime importance. The burn wounds are then cleansed and debrided, and SULFAMYLON

Cream is applied with a sterile gloved hand. Satisfactory results can be achieved with application of the cream once or twice daily, to a thickness of approximately 1/16 inch; thicker application is not recommended. The burned areas should be covered with SULFAMYLON Cream at all times. Therefore, whenever necessary, the cream should be reapplied to any areas from which it has been removed (e.g., by patient activity). The routine of administration can be accomplished in minimal time, since dressings usually are not required, if individual patient demands make them necessary, however, only a thin layer of dressings should be used.

When feasible, the patient should be bathed daily to aid in debridement. A whirlpool bath is particularly helpful, but the patient may be bathed in bed or in a shower.

The duration of therapy with SULFAMYLON Cream depends on each patient's requirements. Treatment is usually continued until healing is progressing well or until the burn site is ready for grafting. SULFAMYLON Cream should not be withdrawn from the therapeutic regimen while there is the possibility of infection. However, if allergic manifestations occur during treatment with SULFAMYLON Cream, discontinuation of treatment should be considered.

If acidosis occurs and becomes difficult to control, particularly in patients with pulmonary dysfunction, discontinuing therapy SULFAMYLON Cream for 24 to 48 hours while continuing fluid therapy may aid in restoring acid-base balance.

### HOW SUPPLIED

16 oz. Plastic Jar (453.6 g) - NDC 16571-723-48 4 oz. Tube (113.4 g) - NDC 16571-723-12 2 oz. Tube (56.7 g) - NDC 16571-723-60 Avoid exposure to excessive heat (temperature above 104° F or 40° C). For External Use Only. Keep this and all medications out of the reach of children. Rx only

#### Manufactured for:

Rising Pharma Holdings, Inc. East Brunswick, NJ 08816

Revised: 08/2020 PIR72348-00

2 oz. (56.7 g)

### PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 16571-723-60

**Rising**<sup>®</sup>

**SULFAMYLON®** Cream (mafenide acetate cream, USP)

#### Rx only For Topical Use Only

Each gram contains mafenide acetate equivalent to 85 mg base in a water-miscible cream of cetyl alcohol, stearyl alcohol, cetyl esters wax, polyoxyl 40 stearate, polyoxyl 8 stearate, glycerin, and water, with methylparaben, propylparaben, sodium metabisulfite,

and edetate disodium as preservatives.

For dosage and administration, read accompanying package insert.

Avoid exposure to excessive heat (temperatures above 104°F or 40°C).

For external use only.

Keep this and all medications out of the reach of children.



SULFAMYLON mafenide acetate cream					
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:16571-723		
Route of Administration TOPICAL					
Active Ingradient/Active Maishy					
Active Ingredient/Active Moiety					

Ingredients     Strengt     Strengt   Strengt </th <th>asis of Strength Strength</th> <th>Basis of S</th> <th>Ingredient Name</th> <th></th>	asis of Strength Strength	Basis of S	Ingredient Name		
Ingredient Name   Strengt     CETYL ALCOHOL (UNII: 936]ST6]CN)   STEARTE (UNII: 13A4J4NH9))   STEARATE (UNII: 13A4J4NH9))     PEG-8 STEARATE (UNII: 2P9L47VISE)   SUSTEARATE (UNII: 2P9L47VISE)   SUSTEARATE (UNII: 2P9L47VISE)     SQLYCERIN (UNII: 920GCA3COOX)   WATER (UNII: 290GCA3COOX)   SUSTEARATE (UNII: 2812SC10H)     VATER (UNII: 590GFOKOR)   METHYLPARABEN (UNII: 2812SC10H)   SODIUM METABISULFITE (UNII: 400N5FNS3C)     SODIUM METABISULFITE (UNII: 400N5FNS3C)   SODIUM (UNII: 7FLD91C86K)   Size     Product Characteristics   Size   Imprint Code     Shape   VHITE (soft white)   Size   Size     Shape   Imprint Code   Marketing Date   Date     Product Characteristics   Imprint Code   Marketing Date   Date     Shape   Int Carton   05/18/2020   Int Carton   Site     NDC:16571-723   1 in 1 CARTON   05/18/2020   Int Carton   Site     NDC:16571-723-   1 in 1 CARTON   05/18/2020   Int Carton   Site     NDC:16571-723-   1 in 1 CARTON   05/18/2020   Int Carton   Site     NDC:16571-723-   1 in 1 CARTON   05/18/2020   Int Carton	ENIDE 85 mg in 1 g	P4L) MAFENIDE	MAFENIDE ACETATE (UNII: RQ6LP6Z0WY) (MAFENIDE - UNII:58447S8		
CETYL ALCOHOL (UNII: 936)ST6)CN)     Image: Stear 1 (UNII: 2488914H1Y)     Image: Stear 1 (UNII: 2488914H1Y)       POLYXYL 40 STEARATE (UNII: 1344)4NH9))     Image: Stear 1 (UNII: 248247V15E)     Image: Stear 1 (UNII: 248247V15E)       GLYCERIN (UNII: 2590/F0K00R)     Image: Stear 1 (UNII: 2590/F0K00R)     Image: Stear 1 (UNII: 2590/F0K00R)       METHYLPARABEN (UNII: 2580/F0K00R)     Image: Stear 1 (UNII: 2580/F0K00R)     Image: Stear 1 (UNII: 2580/F0K00R)       METHYLPARABEN (UNII: 2580/F0K00R)     Image: Stear 1 (UNII: 2580/F0K00R)     Image: Stear 1 (UNII: 2580/F0K00R)       Stear 1 (UNII: 2590/F0K00R)     Image: Stear 1 (UNII: 2580/F0K00R)     Image: Stear 1 (UNII: 2580/F0K00R)       Stear 1 (UNII: 2590/F0K00R)     Image: Stear 1 (UNII: 2580/F0K00R)     Image: Stear 1 (UNII: 2580/F0K00R)       Stear 1 (UNII: 2580/F0K00R)     WHITE (INII: 4V0NSFNS3C)     Stear 1 (UNII: 7FLD91C86K)       Stear 1 USODIUM (UNII: 7FLD91C86K)     Stear 1 (UNII: 500/F0K00R)     Stear 1 (UNII: 500/F0K00R)       Stear 1 USODIUM (UNII: 7FLD91C86K)     Imprint Code     Stear 1 (UNII: 500/F0K00R)       Stear 1 USOR 1 (UNII: 7FLD91C80R)     Verter 1 (UNII: 500/F0K00R)     Stear 1 (UNII: 500/F0K00R)       Stear 1 (USOR 1 (UNII: 7FLD91C80R)     Verter 1 (UNII: 500/F0K00R)     Stear 1 (UNII: 500/F0K00R)       Stear 1 (USOR 1 (UNII: 500/F0K00R)			nts	Inactive Ingree	
CETYL ALCOHOL (UNII: 936)ST6)CN)     Image: Stear 1 (UNII: 24R8914H1Y)     Image: Stear 1 (UNII: 24R8914H1Y)       POLYOXYL 40 STEARATE (UNII: 1344)4NH9))     Image: Stear 1 (UNII: 29L47V15E)     Image: Stear 1 (UNII: 29L47V15E)       GGLYCERIN (UNII: 259GFOKOOR)     Image: Stear 1 (UNII: 259GFOKOOR)     Image: Stear 1 (UNII: 259GFOKOOR)       METHYLPARABEN (UNII: 258Z5C10H)     Sobium METABISULFITE (UNII: 42BX25C10H)     Image: Stear 1 (UNII: 258Z5C10H)       Sobium METABISULFITE (UNII: 42BX25C10H)     Sobium (UNII: 7FLD91C86K)     Image: Stear 1 (UNII: 7FLD91C86K)       Product Characteristics     Size     Image: Stear 1 (UNII: 7FLD91C86K)       Product Characteristics     Size     Imprint Code       Shape     Size     Imprint Code       Flavor     Imprint Code     Date       Contains     Size     Imprint Code       Product     Package Description     Marketing Start     Marketing Date       1 NDC:16571-723- 12     453.6 g in 1 JAR; Type 0: Not a Combination Product     05/18/2020     Imprint Code       2 NDC:16571-723- 12     1 in 1 CARTON     05/18/2020     Imprint Code     Imprint Code       3 NDC:16571-723- 10     1 in 1 CARTON     05/18/2020     Imprint Code     Im	Strength				
STEARYL ALCOHOL (UNII: 2KR8914H1Y)   Image: Stear at a constraint of the state state (UNII: 2PsL47V15E)   Image: Stear at a constraint of the state state (UNII: 2PsL47V15E)     PG-8 STEARATE (UNII: 2PsL47V15E)   Image: Stear at a constraint of the state			-	CETYL ALCOHOL (U	
PEG-8 STEARATE (UNII: 2P9L47VI5E)     Image: Content of Conten					
GLYCERIN (UNII: PDC6A3C00X)   Image: Stress of the stre			<b>FE</b> (UNII: 13A4J4NH9I)	POLYOXYL 40 STE	
water (UNII: 059QF0K00R)   Image: Constant of the second of the secon			2P9L47VI5E)	PEG-8 STEARATE (	
methylparaben (UNII: A2I8C7HI9T)   Image: Content of C			COOX)	GLYCERIN (UNII: PD	
Shape   Size     Flavor   Imprint Code     Contains   Package Description     Marketing Date   Marketing Start Date     Marketing Date   1     NDC:16571-723-   453.6 g in 1 JAR; Type 0: Not a Combination Product   05/18/2020     NDC:16571-723-   1 in 1 CARTON   05/18/2020     Imprint Code   Imprint Code     NDC:16571-723-   1 in 1 CARTON     Imprint Code   Imprint Code     Imprint Code   Marketing Date     Imprint Code   Imprint Code			0R)	WATER (UNII: 059QF	
SOUUM METABISULFITE (UNII: 4VONSFNS3C) EDETATE DISODIUM (UNII: 7FLD91C86K) Product Characteristics Color WHITE (soft white) Score Size Flavor I Inprint Code Contains Flavor V Interview V Int			A2I8C7HI9T)	METHYLPARABEN (	
a   NDC:16571-723   43.6 g in 1 JURE; Type 0: Not a Combination Product   05/18/2020   Marketing Start Product   Marketing Date     a   NDC:16571-723   1 in 1 CARTON   05/18/2020   05/18/2020			Z8IX2SC1OH)	PROPYLPARABEN (	
WHITE (soft white)   Score     Shape   Size     Imprint Code     Flavor   Imprint Code     Color   Marketing Start   Marketing Description     Object 100 Size     Tet Kaging     Marketing Start   Marketing Date     Marketing Start 23 (S g in 1 JAR; Type 0: Not a Combination Product   Object 100 Size     NDC:16571-723   1 in 1 CARTON   Object 100 Size     a NDC:16571-723   1 in 1 CARTON   Object 100 Size   Object 100 Size     a NDC:16571-723   1 in 1 CARTON   Object 100 Size   Object 100 Size     a NDC:16571-723   1 in 1 CARTON   Object 100 Size   Object 100 Size     a NDC:16571-723   1 in 1 CARTON   Object 100 Size   Object 100 Size   Object 100 Size     Size   Size     Imprint Code     Object 100 Size   Marketing Dize </td <td></td> <td></td> <td><b>FE</b> (UNII: 4VON5FNS3C)</td> <td>SODIUM METABISU</td>			<b>FE</b> (UNII: 4VON5FNS3C)	SODIUM METABISU	
Color   WHITE (soft white)   Score     Share   Intervention   Size     Flavor   Imprint Code   Imprint Code     Contains   Package Description   Marketing Start Date   Marketing Date     1   NDC:16571-723 453.6 g in 1 JAR; Type 0: Not a Combination Product   5/18/2020   5/18/2020     2   NDC:16571-723 1 in 1 CARTON   05/18/2020   5/18/2020     3   NDC:16571-723 1 in 1 CARTON   05/18/2020   10			NII: 7FLD91C86K)	EDETATE DISODIUI	
Color   WHITE (soft white)   Score     Shape   Indext (Soft white)   Size     Flavor   Imprint Code   Imprint Code     Cotains   Flavor   Marketing Start   Marketing Date     Imprint Code   State   Marketing Start   Marketing Date     Imprint Code   State   State   State     Imprint Code   State			victics	Dueduct Chaus	
Shape   Size     Flavor   Imprint Code     Contains   Package Description     Marketing Date   Marketing Start Date     Marketing Date   1     NDC:16571-723-   453.6 g in 1 JAR; Type 0: Not a Combination Product   05/18/2020     NDC:16571-723-   1 in 1 CARTON   05/18/2020     Imprint Code   Imprint Code     NDC:16571-723-   1 in 1 CARTON     Imprint Code   Imprint Code     Imprint Code   Marketing Date     Imprint Code   Imprint Code		-			
Imprint Code     Imprint Code   Imprint Code <td></td> <td></td> <td>WHITE (soft white)</td> <td colspan="2"></td>			WHITE (soft white)		
Image: Second all secon				-	
Package DescriptionMarketing Start DateMarketing DateINDC:16571-723- 48453.6 g in 1 JAR; Type 0: Not a Combination Product05/18/2020Marketing DateINDC:16571-723- 121 in 1 CARTON05/18/202005/18/2020III.3.4 g in 1 TUBE; Type 0: Not a Combination Product05/18/2020III.0INDC:16571-723- 121 in 1 CARTON05/18/2020III.3.4 g in 1 TUBE; Type 0: Not a Combination Product05/18/2020	ode	Imprint Code			
#     Item Code     Package Description     Date     Date       1     NDC:16571-723- 48     453.6 g in 1 JAR; Type 0: Not a Combination Product     05/18/2020     05/18/2020       2     NDC:16571-723- 12     1 in 1 CARTON     05/18/2020     05/18/2020       2     MDC:16571-723- 13     1 in 1 CARTON     05/18/2020     05/18/2020       3     NDC:16571-723- 60     1 in 1 CARTON     05/18/2020     05/18/2020				Contains	
#Item CodePackage DescriptionMarketing Start DateMarketing Date1NDC:16571-723- 48453.6 g in 1 JAR; Type 0: Not a Combination Product05/18/202005/18/20202NDC:16571-723- 121 in 1 CARTON05/18/202005/18/20202					
#     Item Code     Package Description     Date     Date       1     NDC:16571-723- 48     453.6 g in 1 JAR; Type 0: Not a Combination Product     05/18/2020     05/18/2020       2     NDC:16571-723- 12     1 in 1 CARTON     05/18/2020     05/18/2020       2     MDC:16571-723- 13     1 in 1 CARTON     05/18/2020     05/18/2020       3     NDC:16571-723- 60     1 in 1 CARTON     05/18/2020     05/18/2020				Packaging	
48   Product   05/16/2020     2   NDC:16571-723- 12   1 in 1 CARTON   05/18/2020     2   113.4 g in 1 TUBE; Type 0: Not a Combination Product   05/18/2020     3   NDC:16571-723- 60   1 in 1 CARTON   05/18/2020		-	Package Description	# Item Code	
12   1111 CARTON   03/16/2020     2   113.4 g in 1 TUBE; Type 0: Not a Combination Product   05/18/2020     3   NDC:16571-723- 60   1 in 1 CARTON   05/18/2020		05/18/2020	6 g in 1 JAR; Type 0: Not a Combination uct		
Product     Product       3     NDC:16571-723- 60     1 in 1 CARTON     05/18/2020       56.7 g in 1 TURE: Type 0: Not a Combination		05/18/2020	1 CARTON		
60 56.7 g in 1 TURE: Type 0: Not a Combination					
56.7 g in 1 TUBE; Type 0: Not a Combination		05/18/2020	1 CARTON		
Product					

# **Marketing Information**

Marketing	Application Number or Monograph	Marketing Start	Marketing End
Category	Citation	Date	Date
NDA	NDA016763	05/18/2020	

Labeler - Rising Pharma Holdings, Inc. (116880195)

# Establishment

Name	Address	ID/FEI	Business Operations
Kavis Pharma LLC		119014974	ANALYSIS(16571-723) , LABEL(16571-723) , MANUFACTURE(16571-723) , PACK(16571-723)

Revised: 7/2023

Rising Pharma Holdings, Inc.